MARKET

CGON

CGON

CG Oncology, Inc.
NASDAQ
53.90
+0.18
+0.34%
Opening 15:40 06/08 EDT
OPEN
54.61
PREV CLOSE
53.72
HIGH
55.52
LOW
53.22
VOLUME
634.16K
TURNOVER
--
52 WEEK HIGH
75.50
52 WEEK LOW
23.65
MARKET CAP
4.75B
P/E (TTM)
-23.0076
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CGON last week (0601-0605)?
Weekly Report · 14h ago
Is CG Oncology (CGON) Centralizing Power To Sharpen Commercial Focus Or Stretch Leadership Too Thin?
Simply Wall St · 1d ago
CG Oncology director Leonard Post sells 1,000 shares for $54,500
PUBT · 3d ago
Assessing CG Oncology (CGON) Valuation After Executive Shakeup And Commercial Leadership Search
Simply Wall St · 5d ago
Oncolytics Biotech names Steve Glover to board of directors
PUBT · 6d ago
Weekly Report: what happened at CGON last week (0525-0529)?
Weekly Report · 06/01 09:15
CG Oncology Leadership Shift Puts Focus On Valuation Gap And Execution
Simply Wall St · 05/30 10:06
CG Oncology CEO to speak at Jefferies Global Healthcare Conference
PUBT · 05/28 20:15
More
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Webull offers CG Oncology Inc stock information, including NASDAQ: CGON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGON stock methods without spending real money on the virtual paper trading platform.